<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994549</url>
  </required_header>
  <id_info>
    <org_study_id>ZP7570-18144</org_study_id>
    <secondary_id>2019-001128-36</secondary_id>
    <nct_id>NCT03994549</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570</brief_title>
  <official_title>A First in Human, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of ZP7570 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single ascending dose trial in&#xD;
      healthy subjects, randomized to ZP7570 or placebo within each cohort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty-four subjects are planned to be studied in eight cohorts in this first-in human trial.&#xD;
      Eight subjects will be allocated to the to eight dose levels. The entire observation period&#xD;
      comprise 28 days starting with a 96 hours in-house stay, where discharge is planned for Day&#xD;
      5, followed by five outpatient visits and an End of Trial Visit at Day 28. A blinded&#xD;
      evaluation of each cohort will be performed by a Trial Safety Group to determine whether the&#xD;
      trial will progress to the next dose level based on the stopping rules specified in protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Actual">November 2, 2020</completion_date>
  <primary_completion_date type="Actual">November 2, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blind, placebo-controlled, single ascending dose trial in healthy subjects, randomized to ZP7570 or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Incidence of adverse events (AEs)</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>The incidence, type and severity of adverse events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the plasma concentration-time curve trough</measure>
    <time_frame>From time zero up to day 28</time_frame>
    <description>AUCτ, Area under the plasma concentration-time curve (AUC) from zero up to trough concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the plasma concentration-time curve infinity</measure>
    <time_frame>From time zero up to day 28</time_frame>
    <description>AUCinf, Area under the plasma concentration-time curve (AUC) from zero up to last concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the plasma concentration-time curve last</measure>
    <time_frame>From time zero up to day 28</time_frame>
    <description>AUClast, Area under the plasma concentration-time curve (AUC) from zero up to last concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum plasma concentration</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Measured maximum plasma drug concentration after dosing, Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Sampling time until reaching Cmax, Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Half-life , t½</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Half-life of ZP7570, t½</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Volume of distribution</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Apparent volume of distribution of ZP7570, Vz/f</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Mean residence time</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Mean residence time, MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Body clearance</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Total body clearance, CL/f</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Elimination rate constant</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Elimination rate constant, λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Plasma glucose levels</measure>
    <time_frame>Time Frame: 0-240 minutes</time_frame>
    <description>Plasma glucose levels included with the acetaminophen at specific timepoints relative to a Mixed Test Meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Insulin concentrations</measure>
    <time_frame>Time Frame: 0-240 minutes</time_frame>
    <description>Insulin concentrations included with the acetaminophen at specific timepoints relative to a Mixed Test Meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Plasma acetaminophen concentration-time curves</measure>
    <time_frame>Time Frame: 0-240 minutes</time_frame>
    <description>Plasma acetaminophen concentration-time curves following ingestion of acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Maximum acetaminophen concentration</measure>
    <time_frame>Time Frame: 0-240 minutes</time_frame>
    <description>Change from baseline acetaminophen to maximum acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Time maximum acetaminophen concentration</measure>
    <time_frame>Time Frame: 0-240 minutes</time_frame>
    <description>Time to maximum change in acetaminophen measure from baseline, Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Safety lab, haematology</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Changes in haematology parameters: Haematocrit, Haemoglobin, Erythrocytes, MCV, MCH, MCHC, platelets, Leucocytes, Neutrophile granulocytes (total count and relative), Lymphocytes (total count and relative), Monocytes (total count and relative), Eosinophile granulocytes (total count and relative), Basophile granulocytes (total count and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Safety lab, clinical chemistry</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Changes in clinical chemistry parameters: Sodium, Potassium, Calcium, Creatinine, Urea, AST, ALT, gamma-GT, Uric acid, Total protein, Albumin, Total bilirubin, Creatine kinase, Alkaline phosphatase, LDH, Total cholesterol, LDL, HDL, Amylase, Triglycerides, Lipase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Safety lab, urinalysis</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Changes in urinalysis: Protein, Glucose Erythrocytes, Leucocytes, pH, ketones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Vital signs, blood pressure</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Changes in vital signs, blood pressure (in mmHG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Vital signs, pulse</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Changes in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Physical examination</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Changes in physical examination of body sections (head, chest and heart, abdomen, skin and mucosae, musculoskeletal system, nervous system, lymph node)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - ECG</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Occurrence of ECG findings, Changes in ECG parameters (in ms). ECG components: Heart rate, PR, QRS, QT and QTcF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Occurrence of Injection site reactions</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Occurrence of injection site reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Immunogenicity: Occurrence of anti-drug antibodies</measure>
    <time_frame>From time zero to 28 days after dosing</time_frame>
    <description>Occurrence of anti-drug antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ZP7570</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual GLP-1/GLP-2 Receptor agonists</intervention_name>
    <description>Eight ascending doses of ZP7570</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>ZP7570</arm_group_label>
    <other_name>ZP7570</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subject aged between 18 and 55 years, both inclusive.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.5 and 28.0 kg/m^2, both inclusive&#xD;
&#xD;
          -  Body weight of at least 60 kg.&#xD;
&#xD;
          -  Heart rate after 5 minutes rest in supine position inside the range of 50-90 beats/min&#xD;
             at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of a disorder which in the investigator's opinion might jeopardize&#xD;
             subjects safety, evaluation of results or compliance with the protocol.&#xD;
&#xD;
          -  History of gallbladder disease or cholecystectomy.&#xD;
&#xD;
          -  History of major depressive disorder or a Patient Health Questionnaire (PHQ-9) &gt; 9&#xD;
             completed at screening, or a history of other severe psychiatric disorders (e.g.&#xD;
             schizophrenia or bipolar disorder).&#xD;
&#xD;
          -  Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale&#xD;
             (C-SSRS) within 6 months prior to screening.&#xD;
&#xD;
          -  Clinically significant abnormal standard 12-lead ECG after 5 min resting in supine&#xD;
             position at screening, including a QTcF &gt; 450 ms (males) or QTcF &gt; 470 ms (females),&#xD;
             PR ≥ 220 ms and QRS ≥ 110 ms as evaluated by the investigator.&#xD;
&#xD;
          -  History of severe hypersensitivity to medicines or foods or history of severe&#xD;
             medicinal/food induced anaphylactic reaction or contraindication to the use of&#xD;
             Indocyanine Green (e.g. hypersensitivity to iodine).&#xD;
&#xD;
          -  Any clinically significant abnormal hematology, biochemistry, or urinalysis screening&#xD;
             tests, as judged by the investigator.&#xD;
&#xD;
          -  TSH values outside of normal reference ranges of safety laboratory&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 90 ml/min/1.73 m2, as defined by Chronic&#xD;
             Kidney Disease Epidemiology Collaboration (CKD-EPI).&#xD;
&#xD;
          -  Known or suspected hypersensitivity to IMP(s) or related products.&#xD;
&#xD;
          -  Systolic blood pressure &lt; 90 mmHg or &gt;139 mmHg and/or diastolic blood pressure &lt; 50&#xD;
             mmHg or &gt; 89 mmHg (one repeat test will be acceptable in case of suspected white-coat&#xD;
             hypertension).&#xD;
&#xD;
          -  Symptoms of arterial hypotension&#xD;
&#xD;
          -  Women of childbearing potential who are not using a highly effective contraceptive&#xD;
             method&#xD;
&#xD;
          -  Men with non-pregnant partner(s) of childbearing potential not willing to use male&#xD;
             contraception (condom) in addition to a highly effective contraceptive method until 28&#xD;
             days after dosing&#xD;
&#xD;
          -  Men with pregnant partner not willing to use male contraception (condom) until 28 days&#xD;
             after dosing, in order to avoid exposure of the embryo/fetus to seminal fluid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Hövelmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Neuss, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <state>North Rhine-Westphalia</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>June 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dual GLP-1R/GLP-2 Receptor agonist</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

